Spyre Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth below.
| ExhibitNumber | Description | Form | File No | Date of Filing | ExhibitNo. | FiledHerewith |
|---|---|---|---|---|---|---|
| 2.1 | Agreement and Plan of Merger, dated June 22, 2023, by and among Aeglea BioTherapeutics, Inc. Aspen Merger Sub I, Inc., Sequoia Merger Sub II, LLC and Spyre Therapeutics, Inc. | S-1 | 333-276251 | 12/22/2023 | 2.1 | |
| 3.1 | Second Amended and Restated Certificate of Incorporation of the Company, effective as of May 14, 2024 | 8-K | 001-37722 | 05/15/2024 | 3.2 | |
| 3.2 | Amended and Restated Bylaws | S-1/A | 333-276251 | 02/05/2024 | 3.2 | |
| 3.3 | Certificate of Designation of Series A Non-Voting Convertible Preferred Stock | S-1 | 333-276251 | 12/22/2023 | 3.3 | |
| 3.4 | Certificate of Designation of Series B Non-Voting Convertible Preferred Stock | S-1 | 333-276251 | 12/22/2023 | 3.4 | |
| 3.5 | Certificate of Amendment to Certificate of Designation of Series B Non-Voting Convertible Preferred Stock | 8-K | 001-37722 | 03/18/2024 | 3.2 | |
| 10.1 | Exchange Agreement, dated April 23, 2024, by and between the Company and Fairmount Healthcare Fund II L.P. | 8-K | 001-37722 | 4/25/2024 | 10.1 | |
| 10.2 | Amendment No. 1 to Novation Agreement, dated April 25, 2024, by and between Paragon Therapeutics, Inc., the Company and WuXi Biologics (Hong Kong) Limited | 10-Q | 001-37722 | 05/09/2024 | 10.6 | |
| 10.3# | α4ß7 (SPY001) License Agreement, dated May 14, 2024, by and between the Company and Paragon Therapeutics, Inc. | X | ||||
| 10.4# | TL1A (SPY002) License Agreement, dated May 14 2024, by and between the Company and Paragon Therapeutics, Inc. | X | ||||
| 10.5# | Second Amended and Restated Antibody Discovery and Option Agreement, dated May 14, 2024, by and between the Company, Paragon Therapeutics, Inc. and Parapyre Holding LLC | X | ||||
| 10.6+ | Form of Stock Option Agreement under the Amended and Restated Spyre Therapeutics, Inc. 2016 Equity Incentive Plan | X | ||||
| 10.7+ | Form of Restricted Stock Unit Award Agreement under the Amended Spyre Therapeutics, Inc. 2018 Equity Inducement Plan | X | ||||
| 31.1 | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 | X | ||||
| ExhibitNumber | Description | Form | File No | Date of Filing | ExhibitNo. | FiledHerewith |
| 31.2 | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 | X | ||||
| 32.1(1) | Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | ||||
| 104 | The cover page from this Quarterly Report formatted in Inline XBRL and contained in Exhibit 101 | |||||
- Indicates management contract or compensatory plan.
Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(1)The certifications on Exhibit 32 hereto are deemed furnished and not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.